Lipigon Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Stefan Nilsson

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	8.3yrs
CEO ownership	1.4%
Management average tenure	no data
Board average tenure	3yrs

Recent management updates

Recent updates

CEO

Stefan Nilsson (44 yo)

8.3yrs

Tenure

Dr. Stefan K. Nilsson serves as the Chief Executive Officer of Lipigon Pharmaceuticals AB since 2016. Dr. Nilsson is an entrepreneur and Co-Founder of Lipigon. Dr. Nilsson has been central in all Lipigon’s...

Board Members

Name	Position	Tenure	Compensation	Ownership
Lars Öhman	Business Development Manager & Chairman	12.3yrs	no data	0.52% SEK 223.5k
Jessica Martinsson	Independent Director	3yrs	no data	0.017% SEK 7.5k
David Westberg	Independent Director	1.3yrs	no data	no data
Johannes Hulthe	Director	3.3yrs	no data	0.16% SEK 68.0k
Maj Hedtjarn	Scientific Advisor	no data	no data	no data
Ludger Scheja	Scientific Advisor	no data	no data	no data
Sander Kersten	Scientific Advisor	no data	no data	no data
Troels Koch	Scientific Advisor	no data	no data	no data
Jorg Heeren	Scientific Advisor	no data	no data	no data
Eva Lindqvist	Independent Director	2.3yrs	no data	0.32% SEK 136.0k

3.0yrs

Average Tenure

60yo

Average Age

Experienced Board: LPGO's board of directors are considered experienced (3 years average tenure).

Lipigon Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

Co-Founder & CEO recently bought kr101k worth of stock

Co-Founder & CEO recently bought kr135k worth of stock

Business Development Manager & Chairman exercised options to buy kr146k worth of stock.

Co-Founder & CEO recently bought kr68k worth of stock

Less than half of directors are independent

No independent directors

Recent updates

Co-Founder & CEO recently bought kr101k worth of stock

The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense

Co-Founder & CEO recently bought kr135k worth of stock

Business Development Manager & Chairman exercised options to buy kr146k worth of stock.

Lipigon Pharmaceuticals AB (Publ) Announces Lipisense Progressing to Phase II Trials

Lipigon Pharmaceuticals AB (Publ) Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ®

Lipigon Applies for Clinical Trial Phase II for Lipisense

New major risk - Revenue and earnings growth

Co-Founder & CEO recently bought kr68k worth of stock

Lipigon Pharmaceuticals AB (publ) Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial

Lipigon Announces Further Positive Data from Phase I Trial of Lipisense

Third quarter 2022 earnings released: kr0.36 loss per share (vs kr1.18 loss in 3Q 2021)

Less than half of directors are independent

Lipigon Pharmaceuticals AB (publ) Announces Positive Top-Line Data from Phase I Clinical Study of Lipisense

Lipigon Pharmaceuticals AB (Publ) Announces Liver-Specific Treatment of Target Protein ANGPTL4 Is Effective and Safe

Lipigon Pharmaceuticals AB Announces First-In-Human Phase I Trial with Lipigon's Lipid-Lowering Candidate Lipisense

Lipigon Receives CTA Approval for Lipid-Lowering Candidate Lipisense

No independent directors

Lipigon Pharmaceuticals AB Confirms Patent Application for Drug Candidate Lipisense in US

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Lipigon Pharmaceuticals AB (publ) Ready to Apply for Clinical Trials After Successful Completion of Preclinical Safety Studies

Lipigon Pharmaceuticals AB (Publ) Completes Another Preclinical Study with Drug Candidate Lipisense

Lipigon Announces Positive Results from Preclinical Study for Lipid-Lowering Drug Candidate Lipisense

Third quarter 2021 earnings: Revenues in line with analyst expectations

Lipigon Expands Collaboration with Hitgen by Selecting Second Target

CEO

Tenure

Board Members

Average Tenure

Average Age